HSA
HRMY icon

HBK Sorce Advisory’s Harmony Biosciences HRMY Stock Holding History

HBK Sorce Advisory’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-400,000
Closed -$401K – 714
2022
Q4 		$401K Buy
400,000
+200,000
+100% +$11M 0.01% 461
2022
Q3 		$198K Buy
+200,000
New +$9.76M 0.01% 463

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

HBK Sorce Advisory's HRMY Position: Q1 2023 in Review

HBK Sorce Advisory sold out of Harmony Biosciences (HRMY) in Q1 2023, closing a stake of 400,000 shares — an estimated $401K sold.

HBK Sorce Advisory first reported a position in HRMY in Q3 2022 and held it in 2 quarters. The position peaked at $401K in Q4 2022. 217 funds tracked by Wall St. Rank hold HRMY as of Q1 2023.

  • HBK Sorce Advisory reported no remaining Harmony Biosciences position as of Q1 2023 after selling out during the quarter.
  • HBK Sorce Advisory sold 400,000 Harmony Biosciences shares in Q1 2023, an estimated $401K.
  • HBK Sorce Advisory first reported a position in Harmony Biosciences in Q3 2022 and held it in 2 quarters.
  • HBK Sorce Advisory's Harmony Biosciences position peaked at $401K in Q4 2022.
  • 217 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2023.

Based on HBK Sorce Advisory's 13F filing for Q1 2023, filed 15 May 2023.